Acne is one of the most common skin conditions seen in general practice. Acne vulgaris—the most prevalent form—affects more ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A multi-center, prospective, open-label, single arm ...

A sebum-selective 1726-nm laser treatment provides year-long control of moderate-to-severe acne across all skin types, with ...

Other therapies may be necessary to remove cysts and fistulae and/ or to correct acne scars. Among them are intralesional steroid injections for cysts, surgery for drainage and excision of pustules ...

Please provide your email address to receive an email when new articles are posted on . Antibiotics were frequently used for longer than the 3- to 4-month duration recommended for acne treatment.

Use of oral spironolactone in women with acne vulgaris was effective and not associated with increased adverse event risk compared with placebo.

The first FDA-approved acne drug with a first-in-class mechanism of action in nearly 40 years launched in the United States in November 2021 after being approved in August 2020. The first-in-class ...

LAVAL, QC / ACCESSWIRE / October 20, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced that the U.S. Food ...

Subject of the leading article in last week’s American Medical Association Journal was acne vulgaris—the blackheads and pimples of adolescence. Dr. Jeffrey Charles Michael, Houston acne specialist who ...

Acne vulgaris remains one of the most pervasive inflammatory skin conditions worldwide, affecting not only adolescents but also adults and contributing to significant psychosocial burden. The ...

LAVAL, QC / ACCESSWIRE / January 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the U.S. launch of CABTREO™ (clindamycin ...

More than 50 million people affected by acne in US each year, with market valued at $5.7 billion in 2024 WOBURN, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” ...